Stockscreener 앱 받기
49.78
2.11%
1.03
시간 외 거래:
50.97
1.19
+2.39%
전일 마감가:
$48.75
열려 있는:
$48.59
하루 거래량:
4.41M
Relative Volume:
2.16
시가총액:
$7.85B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
52.96
EPS:
0.94
순현금흐름:
$245.03M
1주 성능:
+0.30%
1개월 성능:
+1.99%
6개월 성능:
-34.47%
1년 성능:
-35.39%
1일 변동 폭
$47.28
$50.80
1주일 범위
$46.77
$51.54
52주 변동 폭
$46.01
$85.57
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
49.78 | 7.85B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - Stock Titan
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global Challenges - GuruFocus
Bio-Techne Reports Strong Q3 2025 Revenue Growth - TipRanks
Bio-Techne’s Earnings Call: Growth Amid Challenges - TipRanks
Revolutionizing Gene Therapy Protein Expression Potency Assays - Genetic Engineering and Biotechnology News
Bio-Techne Leads Key Proteomic Reagent Markets - Morningstar
Bio-Techne exceeds profit expectations, announces new share buyback plan - MSN
Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c - TipRanks
Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges - TipRanks
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70 - marketscreener.com
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
Earnings call transcript: Bio-Techne beats Q3 2025 EPS forecasts, stock dips - Investing.com
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket - Zacks Investment Research
Bio Techne (TECH) Fell on Negative Funding Environment - Insider Monkey
Is the Options Market Predicting a Spike in BioTechne Stock? - Zacks Investment Research
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance - Investing.com Canada
Bio-Techne Board Approves Share Repurchase Program - Nasdaq
Bio-Techne Reports Q3 2025 Financial Results - TipRanks
Bio-Techne Corporation (TECH) Announces $500 Million Share Repurchase Program - GuruFocus
Bio-Techne Corp (TECH) Q3 Earnings: Adjusted EPS Surpasses Estimates at $0.56, Revenue Slightly Misses at $316.2 Million - GuruFocus
Bio-Techne earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM | TECH Stock News - GuruFocus
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS | TECH Stock News - GuruFocus
Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars - Yahoo Finance
Bio-Techne Corp. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bio-Techne Declares Dividend And New Share Repurchase Program - TradingView
Bio-Techne Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025 - marketscreener.com
Bio-Techne Announces New $500M Share Repurchase Program - TipRanks
Is The Options Market Predicting A Spike In BioTechne Stock? - Barchart.com
ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc. - Quantisnow
Bio-Techne to Host Conference Call on May 7, 2025, to Announce T - GuruFocus
Should You Hold Bio-Techne Corp. (TECH) For the Long Term? - Insider Monkey
TECH Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
ScaleReady Announces March Biosciences as Recipient of G-Rex Grant to Advance Manufacturing of Novel CAR-T Cell Therapy - marketscreener.com
ScaleReady Announces March Biosciences as Recipient of G-Rex® Grant to Advance Manufacturing of Novel CAR-T Cell Therapy - PR Newswire
Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt? - simplywall.st
Bio-Techne's Q3 2025 Earnings: What to Expect - Nasdaq
Bio-Techne's Q3 2025 Earnings: What To Expect - Barchart.com
Innovative Spatial Biology Tools - Trend Hunter
Bio-Techne Corporation (TECH) Slid Due to NIH’s Funding Concerns - Insider Monkey
Bio-Techne Announces Early Access Program for Next-Generation Sp - GuruFocus
Groundbreaking Spatial Protein Detection Technology Transforms Cancer Research: Early Access Now Available - Stock Titan
Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection - marketscreener.com
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.73%
1.07%
자본화:
|
볼륨(24시간):